149 related articles for article (PubMed ID: 29496040)
21. Prognostic value of circulating tumor cells with podoplanin expression in patients with locally advanced or metastatic head and neck squamous cell carcinoma.
Hsieh JC; Lin HC; Huang CY; Hsu HL; Wu TM; Lee CL; Chen MC; Wang HM; Tseng CP
Head Neck; 2015 Oct; 37(10):1448-55. PubMed ID: 24844673
[TBL] [Abstract][Full Text] [Related]
22. Functional invadopodia formation through stabilization of the PDPN transcript by IMP-3 and cancer-stromal crosstalk for PDPN expression.
Hwang YS; Xianglan Z; Park KK; Chung WY
Carcinogenesis; 2012 Nov; 33(11):2135-46. PubMed ID: 22859271
[TBL] [Abstract][Full Text] [Related]
23. Dual role of podoplanin in oral cancer development.
Cîrligeriu L; Cimpean AM; Raica M; Doroş CI
In Vivo; 2014; 28(3):341-7. PubMed ID: 24815836
[TBL] [Abstract][Full Text] [Related]
24. Podoplanin expression predicts prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy.
Kreppel M; Drebber U; Wedemeyer I; Eich HT; Backhaus T; Zöller JE; Scheer M
Oral Oncol; 2011 Sep; 47(9):873-8. PubMed ID: 21767977
[TBL] [Abstract][Full Text] [Related]
25. Expression of podoplanin in oral premalignant and malignant lesions and its potential as a biomarker.
Logeswari J; Malathi N; Thamizhchelvan H; Sangeetha N; Nirmala SV
Indian J Dent Res; 2014; 25(3):305-10. PubMed ID: 25098985
[TBL] [Abstract][Full Text] [Related]
26. Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinomas.
Funayama A; Cheng J; Maruyama S; Yamazaki M; Kobayashi T; Syafriadi M; Kundu S; Shingaki S; Saito C; Saku T
Pathobiology; 2011; 78(3):171-80. PubMed ID: 21613804
[TBL] [Abstract][Full Text] [Related]
27. Platelet CLEC2-Podoplanin Axis as a Promising Target for Oral Cancer Treatment.
Hwang BO; Park SY; Cho ES; Zhang X; Lee SK; Ahn HJ; Chun KS; Chung WY; Song NY
Front Immunol; 2021; 12():807600. PubMed ID: 34987523
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome.
Yuan P; Temam S; El-Naggar A; Zhou X; Liu DD; Lee JJ; Mao L
Cancer; 2006 Aug; 107(3):563-9. PubMed ID: 16804930
[TBL] [Abstract][Full Text] [Related]
29. Expression of podoplanin and vimentin is correlated with prognosis in esophageal squamous cell carcinoma.
Tanaka M; Kijima H; Shimada H; Makuuchi H; Ozawa S; Inokuchi S
Mol Med Rep; 2015 Sep; 12(3):4029-4036. PubMed ID: 26095281
[TBL] [Abstract][Full Text] [Related]
30. Moesin expression by tumor cells is an unfavorable prognostic biomarker for oral cancer.
Barros FBA; Assao A; Garcia NG; Nonogaki S; Carvalho AL; Soares FA; Kowalski LP; Oliveira DT
BMC Cancer; 2018 Jan; 18(1):53. PubMed ID: 29310601
[TBL] [Abstract][Full Text] [Related]
31. Tumor cell expression of podoplanin correlates with nodal metastasis in esophageal squamous cell carcinoma.
Chuang WY; Yeh CJ; Wu YC; Chao YK; Liu YH; Tseng CK; Chang HK; Liu HP; Hsueh C
Histol Histopathol; 2009 Aug; 24(8):1021-7. PubMed ID: 19554509
[TBL] [Abstract][Full Text] [Related]
32. PKA and CDK5 can phosphorylate specific serines on the intracellular domain of podoplanin (PDPN) to inhibit cell motility.
Krishnan H; Retzbach EP; Ramirez MI; Liu T; Li H; Miller WT; Goldberg GS
Exp Cell Res; 2015 Jul; 335(1):115-22. PubMed ID: 25959509
[TBL] [Abstract][Full Text] [Related]
33. Positive and negative regulation of podoplanin expression by TGF-β and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines.
Ohta M; Abe A; Ohno F; Hasegawa Y; Tanaka H; Maseki S; Kondo E; Kurita K; Nakanishi H
Oral Oncol; 2013 Jan; 49(1):20-6. PubMed ID: 22840788
[TBL] [Abstract][Full Text] [Related]
34. Podoplanin expression in oral leukoplakia: tumorigenic role.
de Vicente JC; Rodrigo JP; Rodriguez-Santamarta T; Lequerica-Fernández P; Allonca E; García-Pedrero JM
Oral Oncol; 2013 Jun; 49(6):598-603. PubMed ID: 23473850
[TBL] [Abstract][Full Text] [Related]
35. Expression of Cat Podoplanin in Feline Squamous Cell Carcinomas.
Itai S; Yamada S; Kaneko MK; Harada H; Kagawa Y; Konnai S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Dec; 36(6):243-250. PubMed ID: 29090969
[TBL] [Abstract][Full Text] [Related]
36. Ebp1 activates podoplanin expression and contributes to oral tumorigenesis.
Mei Y; Zhang P; Zuo H; Clark D; Xia R; Li J; Liu Z; Mao L
Oncogene; 2014 Jul; 33(29):3839-50. PubMed ID: 23975429
[TBL] [Abstract][Full Text] [Related]
37. Intercellular contact augments epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3)-activation which increases podoplanin-expression in order to promote squamous cell carcinoma motility.
Fujii M; Honma M; Takahashi H; Ishida-Yamamoto A; Iizuka H
Cell Signal; 2013 Apr; 25(4):760-5. PubMed ID: 23266472
[TBL] [Abstract][Full Text] [Related]
38. Heterocellular N-cadherin junctions enable nontransformed cells to inhibit the growth of adjacent transformed cells.
Sheehan SA; Retzbach EP; Shen Y; Krishnan H; Goldberg GS
Cell Commun Signal; 2022 Feb; 20(1):19. PubMed ID: 35177067
[TBL] [Abstract][Full Text] [Related]
39. Understanding patterns of invasion: a novel approach to assessment of podoplanin expression in the prediction of lymph node metastasis in oral squamous cell carcinoma.
Sharma A; Boaz K; Natarajan S
Histopathology; 2018 Mar; 72(4):672-678. PubMed ID: 29023936
[TBL] [Abstract][Full Text] [Related]
40. Expression of Podoplanin in Sinonasal Squamous Cell Carcinoma and Its Clinical Significance.
Wang H; Hu C; Song X; Hu L; Li W; Yu H; Sun X; Wang D
Am J Rhinol Allergy; 2020 Nov; 34(6):800-809. PubMed ID: 32551858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
